Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 2/20 | 0.43 |
| ▸ | TK2 | O00142 | 2/20 | 0.42 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381255 | 1.00 | SLC6A11 (0.43) | SLC6A11TK2SLC6A1LMNAALDH1A1 | |
| SCHEMBL27443043 | 0.92 | TK2 (0.47) | TK2ALDH1A1KIF11CA12CA1 | |
| SCHEMBL20958136 | 0.92 | TK2 (0.47) | TK2ALDH1A1KIF11CA12CA1 | |
| SCHEMBL9523426 | 0.92 | TK2 (0.47) | TK2ALDH1A1KIF11CA12CA1 | |
| SCHEMBL9524449 | 0.92 | TK2 (0.47) | TK2ALDH1A1KIF11CA12CA1 | |
| SCHEMBL27443036 | 0.92 | TK2 (0.47) | TK2ALDH1A1KIF11CA12CA1 | |
| SCHEMBL4303777 | 0.86 | TK1 (0.43) | TK2ALDH1A1KIF11CYP3A4CYP2C19 | |
| SCHEMBL4013278 | 0.86 | TK2 (0.42) | TK2ALDH1A1KIF11CYP3A4CYP2C19 | |
| SCHEMBL31516447 | 0.80 | TK1 (0.46) | TK2ALDH1A1KIF11CYP3A4CYP2C9 | |
| SCHEMBL20742148 | 0.80 | ALDH1A1 (0.44) | SLC6A11SLC6A1LMNAALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685842-A2 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-6962784-B2 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-0957929-A4 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | GILEAD SCIENCES INC (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | GILEAD SCIENCES, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6426335-B1 | ADMINISTERING COMPLEX OF NUCLEIC ACID LIGAND | GILEAD SCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6168778-B1 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes | NEXSTAR PHARMACEUTICALS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-6051698-A | ARTIFICIAL LIGAND INCLUDES 2'FLUORO MODIFIED NUCLEOTIDES; FOR ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS AGAINST KARPOSI'S SARCOMA, TREATMENT OF MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, SUCCESSOR IN INTEREST TO UNIVERSITY RESEARCH CORPORATION AND/OR UNIVERSITY LICENSE EQUITY HOLDINGS, INC. | 2000-04-18 | — | — | US | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192632-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | SLC6A11 3977/4885TK2 1646/4885SLC6A1 4127/4885 |
| US-20030114404-A1 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | VEGFA, KDR, FLT1 | SLC6A11 3977/4885TK2 1646/4885SLC6A1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.